Incorrect password
evipedia.ai Suggest Edit

DHEA for Health & Longevity

Evidence Review created on 05/03/2026 using AI4L / Opus 4.7

Also known as: Dehydroepiandrosterone, DHEA-S, DHEAS, Prasterone, 3β-hydroxy-5-androsten-17-one

Motivation

DHEA (dehydroepiandrosterone) is the most abundant steroid hormone produced by the adrenal glands and serves as a precursor that the body converts into both testosterone and estrogen. Levels peak in the mid-twenties and decline steadily with age, falling by an estimated 70–80% by the seventh decade of life. This sharp, predictable decline has driven decades of interest in DHEA supplementation as a longevity intervention.

For more than half a century, DHEA has been studied for outcomes spanning mood, sexual function, and bone health. Population-level data have repeatedly linked higher endogenous DHEA levels to lower mortality in older adults, while controlled trials of DHEA supplementation have produced more modest, often mixed, results. A vaginal form (prasterone) is approved for genitourinary symptoms of menopause, and DHEA remains an over-the-counter supplement in the United States while being prescription-only in several other countries.

This review examines what the current evidence shows about DHEA for health and longevity, where the data are convincing, where they are not, and which risks deserve attention.

Benefits - Risks - Protocol - Conclusion

A curated selection of high-quality resources giving accessible overviews of DHEA’s biology, evidence base, and practical use.

  • The Science of How to Optimize Testosterone & Estrogen - Andrew Huberman

    A long-form podcast episode that frames DHEA as a global promoter of sex steroid hormones, explaining how supplemental DHEA can raise both testosterone and estrogen depending on individual aromatase activity and baseline hormone profile, and discussing the case for medical supervision.

  • Did a Recent Study Show We Can Reverse Aging? - Peter Attia

    A critical analysis of the small Fahy TRIIM trial, which combined growth hormone, metformin, and DHEA and reported epigenetic age reversal in older men. Attia is skeptical of the study’s small, uncontrolled design and concludes that the data do not justify clinical use of the combination.

  • The Right and Wrong Way to Treat Hormone Imbalance - Chris Kresser

    An integrative-medicine perspective on DHEA, cortisol, and the HPA (hypothalamic-pituitary-adrenal, the central stress response system) axis, explaining the so-called “pregnenolone steal” framework and emphasizing identification of root causes of hormonal imbalance over isolated DHEA replacement.

  • How Does the Hormone DHEA Impact Longevity - Stephanie Myers

    A long-form review of the epidemiological evidence linking higher DHEA-S (DHEA sulfate, the long-lived sulfated reservoir form of DHEA in blood) levels to lower mortality, including the often-cited finding of an approximately 36% reduction in all-cause death per 100 µg/dL increase in circulating DHEA-S, alongside discussion of cardiovascular, immune, and metabolic effects.

  • DHEA Supplements: Are They Safe? Or Effective? - Jennifer Fisher

    A balanced primer from Harvard Medical School concluding that DHEA has not been convincingly shown to deliver meaningful longevity benefits in healthy adults, while highlighting hormone-sensitive cancer concerns and the value of physician supervision.

No directly relevant standalone overview content from Rhonda Patrick on FoundMyFitness specifically dedicated to DHEA was identified; her platform discusses DHEA chiefly in the context of the TRIIM thymus-regeneration trial and brief Q&A mentions in broader hormone optimization episodes rather than as a primary topic.

Grokipedia

Dehydroepiandrosterone

A comprehensive reference page covering DHEA’s chemistry as 3β-hydroxy-5-androsten-17-one, its biosynthesis from cholesterol via CYP11A1 (a P450 enzyme that performs the side-chain cleavage of cholesterol) and CYP17A1 (a P450 enzyme that converts pregnenolone toward androgen precursors), its sulfation to DHEAS, its peripheral conversion to androgens and estrogens, and its broader physiological roles in metabolic, immune, and neuroactive signaling.

Examine

DHEA

An evidence-graded supplement page summarizing DHEA’s effects across mood, cognition, body composition, sexual function, and cardiovascular biomarkers, noting that benefits are inconsistent in healthy adults but stronger for postmenopausal symptoms and for raising endogenous estrogens and androgens in women over 60.

ConsumerLab

DHEA Supplements Review

An independent product-testing review (last updated February 2026) reporting that the DHEA supplements tested generally contained their labeled amounts within a reasonable margin of error, with labeled doses ranging from 5 mg to 25 mg per capsule and a roughly 10-fold cost spread, plus practical guidance on dosing, safety, and the modest evidence base for mood, sexual function, and bone outcomes.

Systematic Reviews

A selection of the most relevant systematic reviews and meta-analyses examining DHEA across the health and longevity domains where evidence is most concentrated.

Mechanism of Action

DHEA is a 19-carbon (C19) steroid hormone produced primarily in the zona reticularis of the adrenal cortex, with smaller amounts produced in the gonads and brain. After secretion it circulates almost entirely as its sulfated form DHEA-S, which acts as a stable reservoir desulfated on demand in target tissues.

  • Prohormone for sex steroids: DHEA is converted in peripheral tissues — gonads, adipose tissue, skin, brain, and breast — into androstenedione and then into testosterone, dihydrotestosterone (DHT), and the estrogens estrone and estradiol. The local enzymatic environment (3β-HSD (3β-hydroxysteroid dehydrogenase, an enzyme that converts DHEA to androstenedione), 17β-HSD (17β-hydroxysteroid dehydrogenase, an enzyme that interconverts androstenedione and testosterone or estrone and estradiol), aromatase) determines whether a given tissue makes more androgen or more estrogen. This intracrine model — local steroid synthesis from circulating DHEA — is the central pharmacological rationale for supplementation in postmenopausal women, where ovarian estrogen production is essentially absent.
  • Direct nuclear-receptor activity: DHEA itself has weak affinity for androgen and estrogen receptors. Most of its endocrine effects are attributed to its downstream metabolites rather than to the parent molecule.
  • Neurosteroid activity: DHEA and DHEA-S act on the central nervous system as neurosteroids. They are negative allosteric modulators of GABA-A (γ-aminobutyric acid type A, the principal inhibitory neurotransmitter receptor) and positive modulators of NMDA (N-methyl-D-aspartate, an excitatory glutamate receptor), as well as agonists of sigma-1 receptors. These actions are proposed to underlie effects on mood, anxiety, cognition, and stress reactivity.
  • Anti-glucocorticoid effects: DHEA opposes several actions of cortisol on immune cells, neurons, and adipocytes. The DHEA-to-cortisol ratio is sometimes used clinically as a marker of allostatic load (cumulative wear-and-tear from chronic stress), and chronic stress drives a relative deficit of DHEA versus cortisol in the adrenal output.
  • Vascular and metabolic actions: DHEA upregulates endothelial nitric oxide synthase (eNOS, which produces the vasodilator nitric oxide), reduces endothelial inflammatory signaling (NF-κB (nuclear factor kappa B, a master pro-inflammatory transcription factor)), and modulates PPAR-α (peroxisome proliferator-activated receptor alpha, a transcription factor regulating fatty-acid oxidation) and PPAR-γ (the related receptor regulating adipocyte differentiation and insulin sensitivity), with mixed effects on insulin sensitivity in human studies.
  • Immune modulation: DHEA enhances Th1 (T helper type 1) cytokine output and supports natural killer cell function in some preclinical and clinical contexts, with the strongest signal in older adults whose immune function has declined.

Pharmacological properties. DHEA is a small lipophilic steroid (molar mass 288.4 g/mol). Oral DHEA undergoes extensive first-pass sulfation in the gut and liver, so circulating DHEA-S rises rapidly and serves as a long-lived reservoir, while free DHEA peaks within 1–4 hours. The plasma half-life of free DHEA is short (1–6 hours); DHEA-S has a half-life of approximately 7–10 hours and dominates the pharmacokinetics. The sublingual or vaginal route bypasses first-pass metabolism and yields different ratios of DHEA, DHEA-S, testosterone, and estradiol than the oral route. Selectivity is broad rather than receptor-specific, reflecting DHEA’s role as a prohormone. Tissue distribution favors steroidogenic tissues, brain, and adipose tissue. Hepatic metabolism involves sulfotransferases (mainly SULT2A1), 3β-HSD, 17β-HSD, and aromatase; relevant cytochrome P450 enzymes include CYP3A4 (a major liver enzyme that metabolizes many drugs and steroids) and CYP17A1.

Historical Context & Evolution

DHEA was first isolated and characterized in 1934 by Adolf Butenandt and Kurt Tscherning, several decades before its physiological roles were understood. Through the mid-twentieth century, DHEA was studied primarily as a curiosity within steroid biochemistry. The pharmaceutical company Searle marketed it briefly in the 1950s and 1960s as a prescription drug for various symptoms, but it was withdrawn after the 1985 U.S. Anti-Drug Abuse and Dietary Supplement Act tightened regulation of unproven hormone products.

Two key observations reshaped the field. First, in the 1980s and 1990s, large epidemiological studies — including work by Barrett-Connor and colleagues in the Rancho Bernardo cohort — repeatedly found that lower DHEA-S levels were associated with higher all-cause and cardiovascular mortality in older adults, especially men. Second, the 1994 Dietary Supplement Health and Education Act (DSHEA) in the United States allowed DHEA to be marketed as a dietary supplement, opening it to widespread consumer use. The Yen-Friedman 1994 placebo-controlled trial in San Diego, reporting subjective improvements in well-being from DHEA 50 mg/day, further amplified public interest and a wave of longevity-clinic adoption.

Subsequent randomized trials over the following two decades produced a more nuanced picture. Studies such as Nair et al.’s 2006 NEJM trial of DHEA 75 mg/day in older men and women found no meaningful effects on body composition, physical performance, insulin sensitivity, or quality of life. Several small trials in adrenal insufficiency reported modest gains in well-being. Meta-analyses have concluded that systemic DHEA does not significantly affect bone mineral density, body composition, or sexual function in healthy postmenopausal women. Vaginal DHEA (prasterone), by contrast, was approved by the FDA (the U.S. Food and Drug Administration, the federal agency that regulates drugs, devices, and dietary supplements) in 2016 for moderate-to-severe dyspareunia due to genitourinary syndrome of menopause and has demonstrated efficacy in dedicated trials.

Most recently, the small TRIIM trial (Fahy et al., 2019) used a combination of recombinant growth hormone, metformin, and DHEA in older men and reported reductions in epigenetic age, generating headlines but also methodological criticism for the trial’s small size, lack of a control group, and difficulty isolating DHEA’s contribution. The expanded TRIIM-X trial (NCT04375657) is now under way to address some of these limitations. Throughout, the U.S. dietary-supplement framing has coexisted with prescription-only or banned status in many other jurisdictions (e.g., the United Kingdom, Canada, and Australia), where DHEA is treated as a controlled substance or prescription drug.

Expected Benefits

High 🟩 🟩 🟩

Vaginal Symptoms of Genitourinary Syndrome of Menopause

Vaginal DHEA (prasterone, 6.5 mg daily) is FDA-approved for moderate-to-severe dyspareunia (painful intercourse) in postmenopausal women and has consistently improved vaginal pH, vaginal cytology, dryness, and pain across multiple randomized trials. Recent systematic reviews — including Danan et al. (Annals of Internal Medicine, 2024) and Casiano Evans et al. (Obstetrics & Gynecology, 2023) — concluded that vaginal DHEA improves both subjective and objective signs of vaginal atrophy with a tolerability profile comparable to vaginal estrogen. The mechanism is intracrine: locally administered DHEA is converted within vaginal epithelial cells to estrogens and androgens, with negligible systemic exposure.

Magnitude: Moderate-sized improvements in the validated GSM endpoints (vaginal dryness, dyspareunia, and most-bothersome-symptom scores), comparable in size to those produced by low-dose vaginal estrogen across head-to-head comparisons.

Replacement in Adrenal Insufficiency

In women with primary or secondary adrenal insufficiency (e.g., Addison’s disease, hypopituitarism), DHEA replacement at 25–50 mg/day produces small but measurable improvements in health-related quality of life and depressive symptoms. The Alkatib et al. 2009 meta-analysis of 10 randomized trials reported a small effect size for quality of life (effect size 0.21, 95% CI (confidence interval, the range likely to contain the true effect) 0.08–0.33) and a small benefit for depression. The biological rationale is that adrenal insufficiency removes essentially all DHEA production, so replacement restores a hormone otherwise absent.

Magnitude: Effect size of approximately 0.21 (small) for quality of life in women with adrenal insufficiency; small benefit for depression; no significant benefit for anxiety or sexual well-being.

Medium 🟩 🟩

Mood and Depressive Symptoms

The Peixoto et al. 2018 meta-analysis of randomized trials of DHEA in major depression not arising from another medical condition reported a significant overall benefit favoring DHEA over placebo. Earlier work by Schmidt and colleagues (NIH) in midlife-onset minor and major depression and by Bloch et al. in dysthymia is consistent with this signal. The effect is plausibly mediated by neurosteroid actions at GABA-A, NMDA, and sigma-1 receptors. Limitations include small trial sizes, heterogeneous populations, and a paucity of large modern replication studies.

Magnitude: Statistically significant improvement on standardized depression scales versus placebo, with effect sizes typically in the small-to-moderate range across the included randomized trials.

Bone Mineral Density in Older Women ⚠️ Conflicted

Some randomized trials and observational analyses report modest preservation of lumbar-spine and hip bone mineral density with 50 mg/day DHEA over 1–2 years in older women, particularly those with low baseline DHEA-S. Other trials and the Elraiyah et al. 2014 meta-analysis in postmenopausal women with normal adrenal function found no significant effect. The likely modifiers are baseline DHEA-S level, age, and concomitant calcium and vitamin D status.

Magnitude: When positive, lumbar-spine BMD (bone mineral density) gains of 1–3% over 12–24 months versus placebo; null in pooled analyses of postmenopausal women with normal adrenal function.

Low 🟩

Skin Quality and Sebum Production in Older Adults

Small placebo-controlled trials of oral DHEA 50 mg/day for 12 months in older adults (e.g., Baulieu et al., 2000, in DHEAge) reported modest improvements in skin epidermal thickness, hydration, sebum production, and subjective skin appearance, especially in women over 70. Topical DHEA preparations have demonstrated similar effects. The mechanism is local androgen and estrogen generation in the skin.

Magnitude: Small, statistically significant improvements in objective skin parameters (sebum, hydration, thickness) over 6–12 months in older adults; effects in younger adults have not been demonstrated.

Endothelial Function and Arterial Stiffness

Several small randomized trials and mechanistic studies in older men and postmenopausal women report improvements in flow-mediated dilation, reductions in pulse-wave velocity, and lower arterial stiffness with DHEA 50 mg/day for 1–3 months, plausibly via eNOS upregulation and reduced endothelial inflammation. Larger cardiovascular outcome trials are absent.

Magnitude: Small increases in flow-mediated dilation and small decreases in pulse-wave velocity in short-term trials; no demonstrated effect on cardiovascular events.

Insulin Sensitivity and Visceral Adiposity in Older Adults

The Villareal & Holloszy 2004 randomized trial of DHEA 50 mg/day for 6 months in older men and women reported reductions in visceral and subcutaneous fat, with improved insulin sensitivity by oral glucose tolerance test. Replication has been mixed: the Nair et al. 2006 trial found no effect on insulin sensitivity or body composition. Effects, when present, are modest.

Magnitude: Visceral fat reductions of approximately 7–10% in positive trials, with small improvements in insulin sensitivity; null in larger and longer trials.

Subjective Well-being in Older Adults

The DHEAge study (Baulieu et al., 2000) reported subjective improvements in mood, well-being, and libido in women over 70 receiving 50 mg/day oral DHEA for 12 months, with no effect in men or younger women. Other quality-of-life trials have been inconsistent; the Nair et al. 2006 trial and the DAWN study in older adults reported no effect on quality of life or cognitive function.

Magnitude: Modest, statistically significant improvements in self-reported well-being and libido in women over 70; null or inconsistent in men and younger postmenopausal women.

Speculative 🟨

Epigenetic Age Reversal as Part of a Combination Protocol

The small TRIIM trial (Fahy et al., 2019) used recombinant growth hormone, metformin, and DHEA together in 9 men and reported approximately 2.5 years of epigenetic age reversal by GrimAge and other clocks, with thymic regeneration on MRI. Independent contribution of DHEA cannot be isolated, the trial lacked a placebo arm, and the expanded TRIIM-X trial (NCT04375657) is ongoing. Treating DHEA’s role as established would overstate the data.

Immune Function and Vaccine Response

Limited small studies have suggested that DHEA may enhance influenza vaccine antibody responses in older adults and modulate Th1/Th2 (T helper type 1 and 2 immune responses) balance favorably. Replication is incomplete and effect sizes uncertain.

Cognitive Aging in Healthy Adults

The Cochrane review by Huppert and Van Niekerk (later withdrawn for needing an update) and the DAWN trial of DHEA 50 mg/day in older adults (Kritz-Silverstein et al., 2008) found no benefit on cognitive function or quality of life. A coherent benefit signal in cognitively healthy older adults has not emerged.

Benefit-Modifying Factors

  • Sex: Effects on subjective well-being, mood, libido, skin, and bone are most consistently reported in older women, particularly those over 70. In men, randomized trials have generally shown smaller or no effects on body composition and quality of life. The mortality association in observational studies is also stronger in men.
  • Age: Most positive randomized data come from adults aged 60 and older with low baseline DHEA-S. Effects in younger adults with normal endogenous DHEA are minimal and unlikely to justify supplementation in this group.
  • Baseline DHEA-S level: Low baseline DHEA-S is the most consistent predictor of measurable response across mood, bone, and quality-of-life outcomes. Adults with normal-for-age DHEA-S show smaller benefits.
  • Pre-existing health conditions: Adrenal insufficiency (Addison’s disease, hypopituitarism) is the condition where DHEA replacement has the most consistent evidence. Postmenopausal status, particularly with genitourinary symptoms of menopause, is the second-strongest indication, especially for the vaginal route.
  • Genetic polymorphisms: Variants in SULT2A1 (sulfotransferase family 2A member 1, the enzyme that sulfates DHEA), CYP17A1, CYP3A4, and aromatase (CYP19A1) plausibly modify the conversion of supplemental DHEA into downstream androgens and estrogens, but specific pharmacogenetic data in DHEA trials are sparse.
  • Body composition and insulin status: Higher baseline visceral adiposity and insulin resistance are associated with smaller increases in DHEA-S after oral dosing, likely via altered hepatic sulfation and clearance.
  • Concomitant lifestyle factors: Regular physical activity is itself associated with higher endogenous DHEA-S in older adults (De Nys et al., 2023, meta-analysis), so the marginal benefit of supplementation in physically active older adults may be smaller than in sedentary adults with the same baseline level.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Androgenic Side Effects in Women

Oral and transdermal DHEA at 25–50 mg/day in women commonly produces androgenic effects: acne, oily skin, hirsutism (excess facial and body hair, especially on the chin, upper lip, and abdomen), and scalp hair thinning. These are dose-dependent, more common at doses above 25 mg/day, and reversible on discontinuation. The mechanism is peripheral conversion of DHEA to testosterone and dihydrotestosterone in skin and hair follicles.

Magnitude: Reported in approximately 15–30% of women taking 50 mg/day in randomized trials; substantially less common at 10–25 mg/day.

HDL-Cholesterol Reduction (Particularly in Women)

The Qin et al. 2020 meta-analysis of 23 randomized trials reported a significant reduction in HDL-cholesterol of approximately 3 mg/dL overall and approximately 5 mg/dL in women, with no offsetting reduction in LDL-cholesterol or triglycerides. HDL-C is a marker of cardiovascular risk; the clinical significance of small drug-induced HDL-C reductions is debated, but the signal is consistent across trials and worth noting in adults already optimizing cardiovascular risk.

Magnitude: Approximately 3 mg/dL HDL-C reduction overall (95% CI -4.9 to -1.3); approximately 5 mg/dL reduction in women; no significant effect in men.

Medium 🟥 🟥

Estrogenic Side Effects in Women

Higher doses, sublingual delivery, or use in women with high baseline aromatase activity can elevate estradiol enough to produce breast tenderness, mastalgia (breast pain), uterine bleeding, or fluid retention. Prolonged elevation of unopposed estrogen carries a theoretical risk for endometrial hyperplasia. The vaginal prasterone formulation produces minimal systemic estrogen exposure and has not shown consistent endometrial effects in approval trials.

Magnitude: Reported in a minority of women taking 50 mg/day systemic DHEA; rare to absent with 6.5 mg vaginal prasterone.

Hormone-Sensitive Cancer Risk ⚠️ Conflicted

DHEA’s conversion to estrogens and androgens raises a theoretical concern for hormone-sensitive cancers, including breast, endometrial, ovarian, and prostate cancer. Observational data are mixed: some studies link higher endogenous DHEA-S to higher breast or prostate cancer risk, others find inverse associations or no relationship. Clinical trials of DHEA supplementation are too short to evaluate cancer outcomes directly. Major reference sources (Mayo Clinic, Memorial Sloan Kettering) advise against DHEA in patients with current or prior hormone-sensitive cancers.

Magnitude: Not quantified in available studies.

Mood Activation and Insomnia

DHEA can produce activation, irritability, anxiety, and insomnia, particularly with evening dosing or in individuals predisposed to mood activation. In bipolar disorder, case reports describe induction of mania.

Magnitude: Not quantified in available studies.

Low 🟥

Liver Enzyme Elevations

Mild, generally reversible elevations in ALT (alanine aminotransferase, a liver enzyme released into blood when hepatocytes are injured) and AST (aspartate aminotransferase, a related liver enzyme used as a hepatic injury marker) have been reported in a minority of DHEA users. Clinically significant hepatotoxicity is rare. Sublingual and oral formulations differ in first-pass hepatic exposure.

Magnitude: Not quantified in available studies.

Voice Changes and Clitoromegaly (Women)

Long-term high-dose oral DHEA in women can rarely produce deepening of the voice and clitoral enlargement via persistent androgen elevation. These changes can be incompletely reversible.

Magnitude: Rare in trials at 25–50 mg/day; risk increases with higher doses and longer duration.

Product-Quality Variability

Independent testing by ConsumerLab in 2026 found that most tested DHEA supplements contained their labeled amounts within acceptable margins, with one product failing a special-formulation requirement, and that doses varied from 5 mg to 25 mg per capsule across products with up to a 10-fold cost spread. While substantially better than the failure rates seen for some other supplements, accurate dosing still requires vigilance.

Magnitude: Approximately 1 of 6 products tested failing a key quality criterion in the most recent ConsumerLab review; 10-fold cost variation for the same dose.

Speculative 🟨

Cardiovascular Events at Supraphysiologic Doses

The HDL-cholesterol reduction with DHEA, combined with the lack of long-term outcome trials, leaves open the possibility that chronic high-dose DHEA could modestly affect cardiovascular event rates over years to decades. No outcome data confirm or refute this.

Effect on Prostate Hyperplasia and PSA

DHEA’s conversion to dihydrotestosterone has raised concern that it could accelerate benign prostatic hyperplasia or prostate-specific antigen (PSA, a serum marker used to screen for and monitor prostate disease) elevations. Available trial data show small or no PSA changes in older men, but follow-up is short.

Pediatric and Pre-menopausal Healthy Adult Use

Use in healthy adults under 40 lacks meaningful clinical evidence and exposes individuals with intact endogenous production to additional androgen and estrogen load with uncertain long-term consequences.

Risk-Modifying Factors

  • Sex: Women carry the bulk of androgenic and estrogenic side-effect risk and the larger HDL-C reduction; men are at theoretical risk for prostate hyperplasia and PSA elevations. Vaginal prasterone limits systemic exposure and the associated risks.
  • Age: Adults under 40 with normal endogenous DHEA face the worst risk-benefit profile (no demonstrated benefit, ongoing exposure to additional sex steroids). Adults over 60 with low baseline DHEA-S face a more favorable profile, particularly for the indications with strongest evidence.
  • Baseline biomarker levels: Already-low HDL-C, elevated PSA, hormone-sensitive cancer markers (e.g., elevated estradiol, abnormal mammographic findings), or polycystic ovary syndrome features increase risk and modify the case for use.
  • Pre-existing health conditions: Active or prior hormone-sensitive cancer (breast, ovarian, endometrial, prostate), polycystic ovary syndrome, severe acne or hirsutism, bipolar disorder, severe hepatic impairment, and pregnancy or breastfeeding are the most commonly cited contraindications or relative contraindications.
  • Genetic polymorphisms: Variants in CYP17A1, CYP3A4, SULT2A1, and aromatase (CYP19A1) plausibly modify the magnitude of androgen and estrogen rise from DHEA. APOE4 (the ε4 allele of apolipoprotein E, the strongest common genetic risk factor for late-onset Alzheimer’s) and BRCA1/2 (breast-cancer susceptibility genes 1 and 2, conferring high risk for hereditary breast and ovarian cancer) carriers face additional considerations regarding hormone-sensitive cancer risk.

Key Interactions & Contraindications

  • Aromatase inhibitors (letrozole, anastrozole, exemestane): Pharmacodynamic antagonism of the intended estrogen suppression in patients on these agents for breast cancer treatment or prevention. Severity: avoid combination outside a specialist plan; monitor estradiol if combined.
  • Tamoxifen and other selective estrogen receptor modulators (raloxifene, bazedoxifene): Theoretical interference with the intended estrogen-receptor modulation by raising background estrogen exposure. Severity: caution.
  • Insulin and oral hypoglycemics (metformin, sulfonylureas, SGLT2 inhibitors (sodium-glucose co-transporter-2 inhibitors, e.g., empagliflozin), GLP-1 receptor agonists (glucagon-like peptide-1 receptor agonists, e.g., semaglutide)): DHEA can modestly affect insulin sensitivity in either direction. Severity: monitor; adjust antidiabetic dose if blood glucose changes.
  • Antihypertensives (ACE inhibitors such as ramipril, ARBs (angiotensin II receptor blockers, e.g., losartan, valsartan), beta-blockers, calcium channel blockers): DHEA has small variable effects on blood pressure; no systematic interaction is established. Severity: monitor. Clinical consequence: unpredictable shifts in blood pressure (mild hypotension or attenuation of antihypertensive effect) requiring dose adjustment.
  • Oral contraceptives and hormone replacement therapy (estradiol, conjugated equine estrogens, oral progestins): Additive estrogen and androgen exposure. Severity: caution; combine only under specialist supervision.
  • Testosterone replacement therapy (testosterone gel, intramuscular esters): Additive androgenic effects, including acne, hair changes, and prostatic effects. Severity: caution.
  • Anticoagulants and antiplatelets (warfarin, direct oral anticoagulants such as apixaban or rivaroxaban, aspirin, clopidogrel): No specific PK interaction is documented; rare reports of altered INR (international normalized ratio) with warfarin. Severity: monitor. Clinical consequence: shifts in INR with warfarin that could increase bleeding or thrombotic risk.
  • CYP3A4 inhibitors (ketoconazole, ritonavir, grapefruit juice) and inducers (rifampin, carbamazepine, St. John’s wort): May alter DHEA and downstream sex steroid metabolism. Severity: monitor; consider dose reduction with strong inhibitors.
  • Antipsychotics, lithium, and mood stabilizers: DHEA may activate mood and lower seizure threshold modestly; in bipolar disorder, case reports of mania induction exist. Severity: caution; avoid in active bipolar disorder without specialist supervision.
  • Other supplements with hormonal effects (pregnenolone, 7-keto-DHEA, androstenedione, tribulus, fenugreek): Cumulative androgenic or estrogenic burden. Severity: caution.
  • Populations who should avoid DHEA: women and men with current or prior hormone-sensitive cancers (breast, ovarian, endometrial, prostate); individuals with active polycystic ovary syndrome unless under specialist endocrinology care; people with severe hepatic impairment (Child-Pugh Class B or C); pregnant or breastfeeding women; individuals with active bipolar disorder not under specialist psychiatric care; healthy adults under 40 without a documented clinical indication; and adults with elevated baseline PSA awaiting urological evaluation.

Risk Mitigation Strategies

  • Confirmed contraindication screen before use: before any first dose, screen for current or prior hormone-sensitive cancer (breast, ovarian, endometrial, prostate), pregnancy or planned pregnancy, breastfeeding, polycystic ovary syndrome, severe acne or hirsutism, bipolar disorder, severe hepatic impairment (Child-Pugh Class B or C), and elevated baseline PSA awaiting urological workup — to prevent the principal documented and theoretical harms.
  • Measure baseline DHEA-S and reserve supplementation for documented low levels: check serum DHEA-S before starting and limit supplementation to those with age-adjusted low values, since adults with normal-for-age DHEA-S derive minimal benefit while still incurring risk; the strongest mortality and quality-of-life signals are concentrated in the low-DHEA-S subgroup.
  • Start at the lowest effective dose with slow titration: begin at 5–10 mg in the morning, escalating by 5–10 mg every 2–4 weeks if needed up to 25 mg/day; reserve doses of 50 mg/day for adults with adrenal insufficiency or established low DHEA-S under physician supervision — to minimize the dose-dependent androgenic, estrogenic, and HDL-C effects.
  • Prefer the route matched to the indication: use vaginal prasterone (6.5 mg/day) for genitourinary syndrome of menopause to limit systemic exposure; reserve oral DHEA for systemic indications and adrenal insufficiency — to keep systemic hormone levels appropriate and minimize off-target effects.
  • Monitor relevant biomarkers within 8–12 weeks: check serum DHEA-S, total and free testosterone, estradiol, lipid panel (with attention to HDL-C), and (in men over 50) PSA at baseline and 2–3 months after starting — to detect supraphysiologic levels and adverse trends before they become clinically significant.
  • Choose verified-quality products: prefer DHEA from manufacturers with current, public Certificates of Analysis and third-party testing (e.g., USP-verified or ConsumerLab-approved); the 2026 ConsumerLab review showed most products met label claim but that quality is not universal — to mitigate underdosing, overdosing, and adulterant exposure.
  • Avoid evening dosing: take DHEA in the morning with breakfast — to avoid the activation, anxiety, and sleep-fragmentation effects sometimes reported with later-day dosing.
  • Reassess at 3–6 months and discontinue if no benefit: at 3 and 6 months, evaluate the targeted symptom or biomarker; if there is no meaningful change, discontinue rather than escalate, given the absence of long-term outcome data and the cumulative exposure risk.
  • Do not use during pregnancy planning, pregnancy, or breastfeeding: because of the risk of androgenic effects on the fetus and the absence of safety data, avoid DHEA from preconception planning onwards.

Therapeutic Protocol

A standard practitioner-style DHEA protocol used in functional and integrative medicine, and adapted from the geriatric and endocrinology literature, has the following structure:

  • Indication framing: systemic DHEA is most defensible in older adults (typically over 60) with documented low DHEA-S and a specific symptomatic target — low mood, fatigue, sexual dysfunction, or osteopenia in postmenopausal women. Vaginal prasterone (6.5 mg/day) is the indication with the strongest randomized-trial evidence for postmenopausal genitourinary syndrome of menopause. Replacement in adrenal insufficiency is a clinical use under endocrinology supervision.
  • Standard daily dose range — women: typically 5–25 mg/day oral, escalating from 5 mg as tolerated. Doses above 25 mg/day are reserved for adrenal insufficiency under supervision and increase androgenic side-effect risk.
  • Standard daily dose range — men: typically 25–50 mg/day oral; doses above 50 mg/day are not supported by evidence of additional benefit and increase side-effect risk.
  • Vaginal prasterone: 6.5 mg (one ovule) inserted vaginally once daily at bedtime, per the FDA-approved label.
  • Best time of day: with breakfast. Endogenous DHEA secretion follows a diurnal pattern with morning peaks; supplementing in the morning reproduces the natural rhythm and reduces the risk of evening activation and insomnia.
  • Half-life considerations: free DHEA peaks within 1–4 hours after oral dosing with a 1–6 hour half-life; DHEA-S, the long-lived sulfated reservoir, has a 7–10 hour half-life and accumulates over days. Once-daily morning oral dosing produces a stable DHEA-S level appropriate for most chronic uses.
  • Single-dose vs. split-dose: once-daily morning dosing is standard. Split dosing offers no demonstrated advantage and increases the risk of evening activation.
  • Genetic considerations: individuals with known CYP17A1 or CYP19A1 (aromatase) variants may convert DHEA to androgens or estrogens differently, and APOE4 and BRCA1/2 carriers should weigh hormone-sensitive cancer considerations more heavily; pharmacogenetic testing is not routine.
  • Sex differences: women generally need lower doses (5–25 mg/day) than men (25–50 mg/day) and are more susceptible to androgenic effects. The most consistent benefit data in women come from those over 70.
  • Age: use is most defensible at age 60 and older with documented low DHEA-S; the rationale for chronic use in younger healthy adults is weak and unsupported by direct evidence.
  • Baseline biomarkers: before starting, obtain serum DHEA-S, total and free testosterone, estradiol, sex-hormone-binding globulin (SHBG, the protein that transports sex steroids in blood), lipid panel, complete blood count, ALT/AST, and, in men over 50, PSA; in women, a baseline gynecologic exam and (where appropriate) endometrial assessment.
  • Pre-existing health conditions: mild osteopenia, mild or moderate depressive symptoms in postmenopausal women, genitourinary syndrome of menopause (vaginal route), and adrenal insufficiency are the conditions where the protocol is typically applied; hormone-sensitive cancers, polycystic ovary syndrome, and severe hepatic disease modify or preclude it as detailed above.

Where competing therapeutic approaches exist, the main alternatives presented without ranking are:

  • A conventional menopausal management approach using systemic estrogen with or without progesterone for vasomotor and bone symptoms, and low-dose vaginal estrogen for genitourinary symptoms, with no role for DHEA.
  • A guideline-based approach favoring vaginal estrogen, vaginal DHEA (prasterone), or ospemifene for genitourinary syndrome of menopause based on randomized-trial evidence, leaving systemic DHEA as a niche option for low DHEA-S phenotypes.
  • A functional/integrative longevity approach that frames DHEA alongside pregnenolone, melatonin, and other “biogenic” hormones (popularized by groups including Life Extension Foundation, which sells DHEA products and so carries a direct commercial conflict of interest noted here as in section 2), and addresses hormonal balance via lifestyle factors (sleep, exercise, stress management) before adding hormones.

The alternatives also differ substantially in cost: branded vaginal prasterone (Intrarosa) is markedly more expensive than generic vaginal estrogen creams or oral DHEA, so insurers and national health systems have a structural financial incentive to favor cheaper generics over branded prasterone. This payer bias can shape which option is preferred in published guidelines and which receives industry-sponsored research funding, and is a relevant source of structural bias to keep in mind when interpreting comparative evidence.

Discontinuation & Cycling

  • Lifelong vs. short-term: DHEA is generally framed as either a finite trial (3–6 months to assess response) or an ongoing replacement intervention reassessed at least annually. There is no direct evidence supporting open-ended lifelong supplementation in healthy adults, and long-term safety data beyond 1–2 years remain sparse.
  • Withdrawal effects: no formal withdrawal syndrome has been documented. Some users report a transient subjective dip in well-being or libido for 1–2 weeks after stopping, consistent with the half-life of DHEA-S and adjustment of downstream sex steroid levels; objective rebound effects are not established.
  • Tapering protocol: because there is no documented physical dependence, abrupt cessation is generally tolerated. A practical taper for those on doses above 25 mg/day is to halve the dose for 2–4 weeks before stopping to observe the unmasking of mood, libido, or skin changes.
  • Cycling: some practitioners recommend continuous use rather than cycling for replacement indications; others use 3-months-on / 1-month-off schedules in healthy adults to limit cumulative androgen and estrogen exposure. There is no controlled clinical evidence that cycling improves long-term efficacy or safety; it is a precautionary heuristic rather than an evidence-based requirement.
  • Reassessment trigger: if no perceived or measured benefit on the targeted outcome (e.g., DHEA-S, mood scores, GSM symptom score, BMD trajectory) is evident at 3–6 months, discontinuation is preferable to dose escalation, given the limited long-term evidence base.

Sourcing and Quality

  • Regulatory status drives sourcing: DHEA is sold over the counter as a dietary supplement in the United States but is a prescription medicine in the United Kingdom, Canada, Australia, and most of the European Union. Vaginal prasterone (Intrarosa) is FDA-approved as a prescription product. Sourcing decisions should reflect both the user’s jurisdiction and the chosen indication.
  • Third-party testing: independent testing (ConsumerLab, USP) found that most tested DHEA supplements meet label claim, but quality is not universal and one product in the 2026 ConsumerLab review failed a special-formulation criterion. A current Certificate of Analysis (CoA) from an independent laboratory using HPLC (high-performance liquid chromatography) for identity and assay is the minimum acceptable evidence of product content.
  • Form and dose: the canonical pharmaceutical form is micronized DHEA in capsules of 5–50 mg. Sublingual lozenges and transdermal creams alter pharmacokinetics by bypassing first-pass hepatic metabolism, with different ratios of DHEA, DHEA-S, testosterone, and estradiol. Vaginal prasterone is supplied as a 6.5 mg ovule. Avoid undisclosed proprietary blends that obscure DHEA content or pair it with other hormonally active ingredients.
  • Reputable suppliers: in the U.S., USP-verified or ConsumerLab-approved DHEA products from cGMP (current Good Manufacturing Practice, the FDA’s quality-system standards for manufacturing identity, strength, and purity)-registered manufacturers are the safest choice. In jurisdictions where DHEA is prescription-only, branded pharmaceutical products and compounding pharmacies operating under regulated standards offer the highest assurance of identity and dose.
  • Storage and shelf life: store sealed, away from heat, light, and humidity. DHEA is reasonably stable at room temperature in dry conditions; discard products with visible discoloration, off-odor, or past their labeled expiry.

Practical Considerations

  • Time to effect: serum DHEA-S rises within 1–2 weeks of starting oral DHEA and reaches a steady state in 4–6 weeks; subjective effects on mood, energy, and libido, when present, are typically reported within 2–8 weeks; bone-density effects require 12–24 months to detect; vaginal symptom improvement with prasterone typically occurs within 4–12 weeks.
  • Common pitfalls: using systemic DHEA for genitourinary symptoms when the vaginal route is more appropriate; using the same dose in men and women without regard for the larger androgenic burden in women; treating low DHEA-S as a disease in younger adults with normal-for-age levels; ignoring HDL-C trends in cardiovascular-risk-conscious users; relying on store-brand products without third-party testing; using doses above 50 mg/day without a clear clinical indication.
  • Regulatory status: DHEA is sold over the counter as a dietary supplement in the United States (DSHEA-regulated) but is a prescription medicine in the United Kingdom, Canada, Australia, and most of the European Union; vaginal prasterone is FDA-approved as a prescription drug; DHEA is on the World Anti-Doping Agency (WADA) Prohibited List, which can have career consequences for tested athletes.
  • Cost and accessibility: retail oral DHEA in the United States costs roughly USD 0.05–0.50 per 25-mg capsule depending on brand and quality verification; the 2026 ConsumerLab review showed an approximately 10-fold spread for the same dose. Vaginal prasterone is markedly more expensive and typically requires insurance coverage. The compound is broadly accessible online in the U.S. but rarely available through mainstream pharmacies in markets where it is prescription-only.

Interaction with Foundational Habits

  • Sleep: DHEA is mildly activating; the most consistent tolerability complaint is insomnia or sleep fragmentation when dosed in the late afternoon or evening. Direction: blunting of sleep when mistimed; neutral to mildly supportive of daytime energy when timed in the morning. Practical: take with breakfast; avoid evening dosing; if sleep deteriorates, reduce dose or discontinue.
  • Nutrition: DHEA is taken with meals to reduce gastrointestinal upset and minor variability in absorption. Adequate dietary cholesterol and a balanced macronutrient intake support endogenous steroid synthesis upstream of DHEA. Direction: neutral; possibly attenuated benefit on body composition in the setting of poor diet quality. Practical: take with breakfast; ensure adequate protein and nutrient density rather than relying on DHEA for body-composition outcomes.
  • Exercise: regular physical activity raises endogenous DHEA-S in older adults (De Nys et al., 2023, meta-analysis), so the marginal benefit of supplementation is smaller in physically active adults. As a WADA-prohibited substance, DHEA is incompatible with tested competitive sport. Direction: indirect — exercise itself raises DHEA-S; supplementation adds little in active older adults. Practical: prioritize a structured resistance-and-cardio program; do not use DHEA within any in-competition window for tested athletes.
  • Stress management: chronic psychological stress lowers DHEA and DHEA-S relative to cortisol, contributing to elevated allostatic load. DHEA modestly opposes glucocorticoid actions, and exercise, sleep, and stress-reduction practices (e.g., mindfulness, breathwork) raise endogenous DHEA-S. Direction: potentiating with stress-reduction practices. Practical: pair the protocol with structured stress-reduction (sleep hygiene, breathwork, exercise) and reassess whether ongoing supplementation is needed once these habits are in place.

Monitoring Protocol & Defining Success

Baseline testing and ongoing monitoring focus on confirming a clinical rationale for DHEA, detecting hormonal imbalance and lipid effects, and tracking the targeted symptomatic outcome.

Baseline testing before starting includes serum DHEA-S, total and free testosterone, estradiol, sex-hormone-binding globulin (SHBG), a fasting lipid panel (with attention to HDL-C), liver enzymes (ALT/AST), fasting glucose and HbA1c (glycated hemoglobin, a 3-month average of blood glucose), complete blood count, and, in men over 50, prostate-specific antigen (PSA); in women, age- and risk-appropriate breast and gynecologic assessment.

Ongoing monitoring proceeds at 4 weeks (focused symptom and tolerability check, blood pressure, mood), 12 weeks (full hormone panel and lipid panel, repeat PSA in men over 50, repeat targeted symptom assessment), 6 months (repeat hormone and lipid panels, bone density baseline if BMD is the indication), and annually thereafter for as long as the intervention continues.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Serum DHEA-S Women 50–70 years: 100–250 µg/dL; Men 50–70 years: 200–400 µg/dL; aim for mid-young-adult range Confirms low-baseline rationale and detects supraphysiologic levels Conventional age-adjusted reference ranges decline with age; functional targets aim for mid-young-adult levels; measure morning, fasting; assess at baseline, 12 weeks, then annually
Total testosterone Women: 30–70 ng/dL; Men: 600–900 ng/dL (total) Detects androgenic over-conversion; rises after DHEA dosing Conventional ranges are wider; functional targets are tighter; measure morning, fasting; combine with free testosterone and SHBG for interpretation
Estradiol (E2) Postmenopausal women: 10–50 pg/mL; men: 20–40 pg/mL Detects estrogenic over-conversion; relevant to breast and endometrial risk Higher values may flag aromatase activity or excess DHEA dose; measure morning
HDL-cholesterol Women > 60 mg/dL; Men > 50 mg/dL Detects the most consistent unfavorable lipid effect of DHEA Conventional cutoffs are slightly lower (women ≥ 50, men ≥ 40 mg/dL); functional targets are tighter; measure fasting at baseline and 12 weeks
Fasting lipid panel (TC, LDL-C, TG) Per individual cardiovascular risk; LDL-C: discuss with clinician Tracks broader lipid response Measure fasting; functional targets depend on cardiovascular risk profile
Prostate-specific antigen (PSA, men > 50) < 2.5 ng/mL Detects DHT-driven prostatic effects in men Conventional age-adjusted upper limits are higher; functional target is tighter; measure at baseline and 6–12 months
ALT / AST ALT < 25 U/L (men), < 19 U/L (women); AST < 25 U/L Confirms hepatic capacity for DHEA metabolism Conventional reference upper limit is ~40 U/L; functional optimum is lower
Fasting glucose & HbA1c Fasting glucose 70–90 mg/dL; HbA1c < 5.4% Tracks the variable insulin-sensitivity effect of DHEA Conventional cutoffs are < 100 mg/dL and < 5.7%; functional targets are tighter; measure fasting
Targeted symptom score (e.g., PHQ-9 for mood; FSFI for sexual function; GSM symptom score for vaginal symptoms) Personal baseline; trend, not population norm Tracks the actual clinical outcome being targeted PHQ-9 is the Patient Health Questionnaire-9, a validated 9-item depression screen; FSFI is the Female Sexual Function Index, a 19-item validated questionnaire; use a fasting morning test, same instrument and time of day; assess at baseline, 4 weeks, 12 weeks, and 6 months
Bone mineral density (DEXA of lumbar spine and hip) T-score > -1.0 (within 1 SD of young-adult mean); trend matters Tracks BMD trajectory if osteopenia is the indication DEXA is dual-energy X-ray absorptiometry, the standard imaging method for measuring bone mineral density; conventional thresholds: -1.0 to -2.5 osteopenia, < -2.5 osteoporosis; measure at baseline and 12–24 months

Qualitative markers to track alongside the table:

  • Subjective mood, energy, and motivation
  • Libido, ease of arousal, and (in postmenopausal women) vaginal comfort
  • Skin oiliness, acne, and changes in hair pattern (face, scalp, body)
  • Sleep quality and morning refreshment
  • Breast tenderness, mastalgia, or unexpected uterine bleeding (immediate evaluation triggers)
  • Voice changes (women) — immediate evaluation trigger
  • Mood activation, irritability, or hypomanic features (immediate evaluation trigger)

Emerging Research

  • Thymus regeneration and epigenetic age reversal (TRIIM-X): NCT04375657 is the expanded follow-up to the 2019 TRIIM trial, testing personalized recombinant growth hormone, metformin, and DHEA in 85 older adults to evaluate biomarkers of immunosenescence (age-related decline in immune function) and epigenetic aging over 12 months. A controlled positive result would directly inform the longevity case for DHEA as part of a combination protocol.
  • Slow-release DHEA in inflammatory disease: NCT07179952 is a Phase 2 trial of slow-release DHEA versus placebo in asthma, building on the rationale that glucocorticoid therapy suppresses endogenous DHEA. A positive result could broaden DHEA’s clinical role into glucocorticoid-induced DHEA deficiency more generally.
  • Vaginal prasterone in breast cancer survivors: NCT06611514 is a Phase 3 trial of vaginal prasterone for genitourinary syndrome of menopause in breast cancer survivors on aromatase inhibitors, a population in which traditional vaginal estrogen is contraindicated. A positive outcome would provide a much-needed evidence-based option for this group.
  • DHEA combinations in diminished ovarian reserve: NCT07535983 and a network meta-analysis (Conforti et al., 2025) continue to evaluate DHEA as an adjuvant in poor responders to ovarian stimulation; this is outside the longevity remit but informative about DHEA’s tissue-level estrogen and androgen pharmacology.
  • DHEA and chronic-pain neurosteroid science: NCT05935761 is a Phase 2 randomized trial of pregnenolone, DHEA, and placebo for chronic low back pain in U.S. military veterans, leveraging DHEA’s neurosteroid actions. Future evidence could clarify whether DHEA has a role beyond hormone replacement.
  • Mortality and biomarker meta-analyses: Li et al., 2020 provides the most recent meta-analytic confirmation of low DHEA-S as a marker of higher all-cause and cardiovascular mortality; a corollary line of work (McCrory et al., 2023) is integrating DHEA into composite “allostatic load” and “biological age” indices that may eventually be more useful clinically than DHEA-S alone.
  • Quality and surveillance of supplements: Danan et al., 2024 and ongoing ConsumerLab updates continue to refine the evidence base for vaginal versus systemic DHEA in genitourinary syndrome of menopause and the practical quality landscape of over-the-counter DHEA products.

Conclusion

DHEA is the most abundant adrenal steroid hormone in young adults and a precursor that the body converts into both testosterone and estrogen. Its production declines steeply with age, and lower endogenous levels have repeatedly been linked to higher mortality in older adults. The evidence for supplementing DHEA, however, is uneven. Vaginal prasterone for the genitourinary symptoms of menopause and replacement in adrenal insufficiency are the indications with the strongest randomized-trial support. Effects on mood, bone, skin, and arterial stiffness are smaller and more inconsistent, and meta-analyses of DHEA in postmenopausal women with normal adrenal function show no clear benefit on libido, lipids, or bone density.

For health- and longevity-oriented adults, DHEA occupies an unusual position: long history, broad commercial availability in the United States, prescription-only or banned in many other jurisdictions, hormonally active in ways that produce both predictable benefits and predictable side effects. The most reliably observed unfavorable effect is a reduction in protective (“good”) cholesterol, particularly in women, and the most prominent theoretical concern is hormone-sensitive cancer risk. Much of the older promotional literature comes from sources with direct commercial conflicts of interest, including major supplement publishers, which colors the evidence base. The current evidence supports treating DHEA as a targeted, monitored intervention for specific subgroups rather than as a general longevity supplement.

Top - Benefits - Risks - Protocol